+1 Recommend
0 collections
      • Record: found
      • Abstract: not found
      • Article: not found

      The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients

      , , , , , , , , , , , , , , written on behalf of AME Lung Cancer Collaborative Group
      Translational Lung Cancer Research
      AME Publishing Company

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          <div class="section"> <a class="named-anchor" id="d6230819e444"> <!-- named anchor --> </a> <h5 class="section-title" id="d6230819e445">Background</h5> <p id="d6230819e447">We conducted a meta-analysis to systematically evaluate the relationship between programmed death-ligand 1 (PD-L1) expression and survival in patients with lung cancer. </p> </div><div class="section"> <a class="named-anchor" id="d6230819e449"> <!-- named anchor --> </a> <h5 class="section-title" id="d6230819e450">Methods</h5> <p id="d6230819e452">The electronic databases PubMed, Embase, Cochrane, and Web of Science were searched up to January 2 <sup>nd</sup>, 2018, for articles relating to PD-L1 expression detected by immunohistochemistry (IHC) and lung cancer patient prognosis. </p> </div><div class="section"> <a class="named-anchor" id="d6230819e457"> <!-- named anchor --> </a> <h5 class="section-title" id="d6230819e458">Results</h5> <p id="d6230819e460">Fifty studies including 11,383 patients published between 2011 and 2017 were enrolled in this meta-analysis. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) suggested that PD-L1 IHC expression was related to poor overall survival (OS) (HR =1.45, 95% CI: 1.24–1.68). In subgroup analysis categorized according to sample type, cut-off value, ethnicity and TNM stage, the pooled results demonstrated inferior survival in the PD-L1 positive group when the PD-L1 expression was detected by resection specimens (P=0.000), 5% was taken as the cutoff value (P=0.000), the patients were in early stage (I–III) (P=0.000), and the geographic setting of the study was in Asia (P=0.000). Besides, patients with high PD-L1 expression had shorter OS in NSCLC (P=0.000), ADC (P=0.000), SCC (P=0.353) and LELC (P=0.810), while no significant difference was observed in SCLC (P=0.000). The pooled odds ratios (ORs) suggested that PD-L1 expression was associated with male (P&lt;0.001), smoker (P&lt;0.001), poor tumor differentiation (P=0.014), large tumor size (P=0.132), positive lymph nodal metastasis (P=0.002), <i>EGFR</i> wild-type status (P&lt;0.001) and <i>KRAS</i> mutations (P=0.393). However, age (P=0.15) and <i>ALK</i> rearrangements (P=0.567) had no bearing on PD-L1 expression. </p> </div><div class="section"> <a class="named-anchor" id="d6230819e471"> <!-- named anchor --> </a> <h5 class="section-title" id="d6230819e472">Conclusions</h5> <p id="d6230819e474">PD-L1 expression that is associated with several clinicopathological feactures may serve as a poor prognostic biomarker for patients with lung cancer. </p> </div>

          Related collections

          Author and article information

          Translational Lung Cancer Research
          Transl. Lung Cancer Res.
          AME Publishing Company
          August 2019
          August 2019
          August 2019
          August 2019
          : 8
          : 4
          : 429-449
          © 2019
          Self URI (article page): http://tlcr.amegroups.com/article/view/31056/22127


          Comment on this article